All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

  TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche and sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer.   View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

How do patient characteristics, T cell starting material, and drug product attributes affect CAR T-cell therapy outcomes?

By Paola Frisone

Share:

Sep 7, 2020


Little is known about the effect of patient characteristics, T cell starting material, and chimeric antigen receptor (CAR) T drug product attributes on the efficacy, safety, and pharmacokinetics (PK) of CAR T cells.

To understand how these features affect CAR T-cell therapy outcomes, random forest-based multifactorial analyses were performed on data from 172 patients with relapsed/refractory (R/R) large B cell lymphoma (LBCL), who were enrolled in the phase 1 TRANSCEND-NHL-001 (NCT02631044) study and treated with the CD19-directed CART cell product, lisocabtagene maraleucel (liso-cel).1

Methods1

The key objectives of the study were, PK, progression-free survival (PFS), duration of response (DOR), complete response (CR), objective response (OR), and safety. Features considered were: T cell starting material and drug product characteristics (CMC), patient demographic features and blood chemistry (clinical), and CMC plus clinical (all).

Random forest regression classification and random survival forest were used to model clinical endpoints, to assess attribute importance, and outcome dependency on each attribute tested.

Results1

Clinical and CMC attributes that demonstrated associations with PK:

  • Age, with younger patients experiencing higher CAR T-cell expansion
  • Number of prior treatments, with patients receiving fewer lines of prior treatments experiencing higher CAR T-cell expansion
  • Effector cytokine secretion, with less effector cytokine secretion in CD8+ drug products (more naive-like phenotype) being associated with higher CAR T-cell expansion

Clinical and CMC attributes that demonstrated associations with efficacy:

  • Higher functional cytokine production of the liso-cel drug product was associated with longer PFS and a higher chance of achieving CR
  • Patients with lower tumor burden, LBCL transformed from follicular lymphoma (FL) or primary mediastinal B-cell lymphoma (PMBCL) achieved longer PFS. Patients with lower tumor burden were also more likely to achieve CR

Clinical and CMC attributes that demonstrated associations with adverse events:

  • Patients with higher tumor burden, or those needing bridging therapy between apheresis and infusion, were more prone to experiencing neurotoxicity or cytokine release syndrome of any grade

Conclusion

The results of this study showed that patient and manufacturing characteristics, such as tumor burden and functional cytokine production of the CAR-T drug product, were the most important attributes associated with liso-cel CAR T-cell expansion, efficacy, and safety in patients with R/R LBCL treated in the TRASCNEND-NHL-001 trial. These results might help with the early identification of specific patient populations that will benefit the most from CAR T-cell therapy and thus improve its clinical experience and outcomes.

References

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

Your opinion matters

Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?